Clinical Trials Browser

Triple Negative Breast Neoplasms × Paclitaxel × 1 year × Clear all

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06926868 2026-03-11

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT06604858 2026-03-09

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Phase 1/2 Active not recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06279364 2026-01-27

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06078384 2025-11-17

ETNA

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02593175 2025-11-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

Phase 2 Completed

43 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT06845319 2025-10-22

NeoCARD

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05768932 2025-10-15

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT02876107 2025-10-10

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01982448 2025-09-30

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase 2 Completed

147 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT05382299 2025-09-05

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04083963 2025-07-10

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04331067 2025-04-23

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Phase 1/2 Active not recruiting

15 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT06637306 2025-03-26

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms